Eli Lilly and Company (LLY)vsRadNet Inc (RDNT)
LLY
Eli Lilly and Company
$1,131.42
-0.26%
HEALTHCARE · Cap: $948.95B
RDNT
RadNet Inc
$54.34
+2.90%
HEALTHCARE · Cap: $4.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 3269% more annual revenue ($72.25B vs $2.14B). LLY leads profitability with a 35.0% profit margin vs -0.7%. RDNT appears more attractively valued with a PEG of 0.96. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
RDNT
Buy54
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Earnings expanding 75.0% YoY
Growing faster than its price suggests
Revenue surging 22.1% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Elevated debt levels
Weak financial health signals
ROE of -1.3% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : RDNT
The strongest argument for RDNT centers on EPS Growth, PEG Ratio, Revenue Growth. Revenue growth of 22.1% demonstrates continued momentum. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : RDNT
The primary concerns for RDNT are Debt/Equity, Piotroski F-Score, Return on Equity. Debt-to-equity of 1.79 is elevated, increasing financial risk.
Key Dynamics to Monitor
RDNT carries more volatility with a beta of 1.39 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 54/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →RadNet Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
RadNet, Inc., provides outpatient imaging services in the United States. The company is headquartered in Los Angeles, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?